Ionis Pharmaceuticals has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. Source: BioSpace
Australia’s Therapeutic Goods Administration will impose heavier sanctions for violations of its regulations on drug advertising, but the agency also will phase out its requirement that certain drug advertisements be…
The U.K.’s Medicines and Healthcare products Regulatory Agency released new guidance on its approach to GXP data integrity and its expectations for achieving compliance. Source: Drug Industry Daily
A federal judge ruled a proposed class action accusing Walgreens of overcharging for generic drugs must go forward. Source: Drug Industry Daily
A bipartisan bill introduced in the Senate would widen the Drug Enforcement Administration’s discretion in setting opioid production quotas, allowing the DEA to factor abuse rates and overdose deaths into…
The House of Representatives failed to pass the latest iteration of federal right-to-try legislation Tuesday night. Source: Drug Industry Daily
Federal right-to-try legislation that would have allowed terminally ill patients access to experimental therapies without approval from the U.S. Food and Drug Administration failed to muster enough support in the…
Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals has secured $63.5 million in Series B financing. Source: BioSpace
Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work. Source: BioSpace
Auris Medical has gone down swinging again in attempting to develop a treatment for tinnitus after it announced its Phase III trial failed to meet endpoints. Source: BioSpace